Publications by authors named "Yairis Fernandez"
Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size proteoliposomes adjuvant (VSSP); and 350 μL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the Heberprovac in advanced prostate cancer patients as well as its capacity to induce anti-GnRH antibodies, the subsequent effects on serum levels of testosterone and PSA and the patient overall survival.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined a prostate cancer vaccine combining Montanide ISA 51 and very small size proteoliposomes (VSSP), showing it generates a strong immune response against gonadotropin-releasing hormone (GnRH) in healthy mice.
- - When tested on DD/S mice with Shionogi carcinoma (SC) 115 cells, the vaccine led to sustained tumor growth inhibition compared to non-vaccinated controls, with some mice experiencing complete remission.
- - The research indicates that the vaccine's ability to moderately reduce testosterone levels could help delay the development of castration resistance in prostate cancer, proposing it as a potential treatment option for patients.